Hsu H Y, Chang M H, Hsieh R P, Ni Y H, Chi W K
Department of Emergency Medicine, College of Medicine, National Taiwan University, Taipei.
Hepatology. 1996 Dec;24(6):1355-60. doi: 10.1002/hep.510240607.
The immune responses to hepatitis B vaccine were studied in 11 hepatitis B surface antigen (HBsAg) carrier children who had cleared HBsAg but failed to develop hepatitis B surface antigen antibodies (anti-HBs) in sera (group 1), 5 HBsAg carrier children who had cleared HBsAg and developed detectable anti-HBs in sera (group 2), and 5 healthy subjects seronegative for all hepatitis B virus (HBV) markers (group 3). After receiving three doses of HB vaccine, group 1 subjects failed to develop detectable anti-HBs. Subsequently, each subject of the three groups was given one dose of the same vaccine for a cellular immunity study, and a measurable proliferation of peripheral blood mononuclear cells (PBMC) to HBsAg was detected in 1 of 8 (12.5%), 0 of 5, and 4 of 5 (80%) of the cases in each group, respectively, after vaccination. The removal of CD8+ cells enhanced the HBsAg blastogenic response in group 3 but did not reverse the unresponsiveness in group 1 and group 2 subjects. The addition of interleukin (IL)-2 in culture reversed unresponsiveness in all cases except one case in group 1. Compared with before vaccination, PBMC from group 2 subjects produced significantly less interferon gamma (IFN-gamma) and more IL-4 in response to HBsAg after vaccination, a cytokine response not observed in group 1 subjects. HLA typing indicated that 3 of 10 patients in group 1 (30%) and 1 of 5 patients in group 2 (20%) had HLA-DRw14-DRw52, a marker previously linked to low anti-HBs response to hepatitis B vaccine in Taiwan. We conclude that the underlying causes of poor anti-HBs response in group 1 subjects are multifactorial, including specific failure of antigen presentation or T-cell activation, or the lack of T helper (Th)2 cell-like response to HBsAg. HLA-DRw14-DRw52 does not confer absolute nonresponsiveness to HBsAg. These patients are not benefited by hepatitis B immunization.
对11名清除了乙肝表面抗原(HBsAg)但血清中未产生乙肝表面抗原抗体(抗-HBs)的乙肝表面抗原携带者儿童(第1组)、5名清除了HBsAg且血清中产生可检测到的抗-HBs的乙肝表面抗原携带者儿童(第2组)以及5名所有乙肝病毒(HBV)标志物均为血清阴性的健康受试者(第3组)的乙肝疫苗免疫反应进行了研究。在接种三剂乙肝疫苗后,第1组受试者未产生可检测到的抗-HBs。随后,三组中的每位受试者均接种一剂相同疫苗以进行细胞免疫研究,接种疫苗后,每组分别有8例中的1例(12.5%)、5例中的0例以及5例中的4例(80%)检测到外周血单个核细胞(PBMC)对HBsAg有可测量的增殖。去除CD8+细胞增强了第3组中对HBsAg的增殖反应,但未逆转第1组和第2组受试者的无反应性。在培养中添加白细胞介素(IL)-2逆转了除第1组1例之外所有病例的无反应性。与接种疫苗前相比,第2组受试者的PBMC在接种疫苗后对HBsAg产生的干扰素γ(IFN-γ)显著减少,而白细胞介素-4增多,第1组受试者未观察到这种细胞因子反应。HLA分型显示,第1组10例患者中有3例(30%)以及第2组5例患者中有1例(20%)具有HLA-DRw14-DRw52,这是先前在台湾与乙肝疫苗抗-HBs反应低下相关的一个标志物。我们得出结论,第1组受试者抗-HBs反应不佳的潜在原因是多因素的,包括抗原呈递或T细胞活化的特定缺陷,或缺乏对HBsAg的辅助性T(Th)2细胞样反应。HLA-DRw14-DRw52并不导致对HBsAg绝对无反应。这些患者无法从乙肝免疫接种中获益。